SCHEMBL26445397

SCHEMBL26445397

CCCOCCOCCOCCOCCOCCOCCC(=O)Nc1ccc(COC(=O)Oc2ccc(N)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 6/20 0.42
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
GLA P06280 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
CASP6 P55212 1/20 0.41
GFER P55789 1/20 0.41
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 2/20 0.39
PKM P14618 1/20 0.39
LTA4H P09960 2/20 0.39
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26445737 0.78 MAPT (0.47) MEN1KMT2AMAPTGAATDP1
SCHEMBL25680277 0.78 HPGD (0.47) MEN1KMT2AMAPTTDP1ALDH1A1
SCHEMBL11315413 0.78 L3MBTL1 (0.52) GAAALDH1A1L3MBTL1LMNARAB9A
SCHEMBL23515130 0.76 KMT2A (0.45) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL29932573 0.73 ALDH1A1 (0.53) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL25680273 0.73 LTA4H (0.43) MEN1KMT2AMAPTGAATDP1
SCHEMBL25680280 0.73 TP53 (0.46) MEN1KMT2AMAPTGAATDP1
SCHEMBL23417986 0.71 MAPT (0.46) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL23417892 0.71 MAPT (0.46) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL26444826 0.69 ALDH1A1 (0.44) KMT2AMAPTTDP1THRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES KLEO PHARMACEUTICALS, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128688-A1 DIRECTED CONJUGATION TECHNOLOGIES CD2BP2, CD2, CD47 MEN1 2845/4885KMT2A 310/4885MAPT 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.